c-Myc

Myc

The transcription factor c-Myc is a member of the basic helix-loop-helix leucinezipper (bHLHZip) protein family. The target genes of the c-MYC protein participate in different cellular functions, including cell cycle, survival, protein synthesis, cell adhesion, and micro-RNA expression. c-Myc is also one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS) cells and is implicated in maintaining cancer stem-like cells (CSCs). Most biological functions of c-Myc require heterodimerization with its activation partner Max.

c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. Deregulated expression of c-MYC caused by gene amplification, retroviral insertion, or chromosomal translocation is associated with tumorigenesis. c-Myc has been identified as a highly promising target for cancer therapy.

c-Myc Inhibitors

10058-F4

Cat. No.: HY-12702

10058-F4 is a **c-Myc** inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

10074-A4

Cat. No.: HY-124129

10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc$_{370-409}$ at different sites along the peptide chain. 10074-A4 has anticancer effects.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

10074-G5

Cat. No.: HY-100996

10074-G5 is an inhibitor of **c-Myc-Max** dimerization with an **IC$_{50}$** of 146 μM.



Purity: 96.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

APTO-253

(LOR-253; LT-253)

Cat. No.: HY-16291

APTO-253 (LOR-253) is a small molecule that inhibits **c-Myc** expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and **apoptosis** in acute myeloid leukemia cells.



Purity: 98.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BRD4 Inhibitor-18

Cat. No.: HY-146660

BRD4 Inhibitor-18 is a highly potent **BRD4** inhibitor with an **IC$_{50}$** value of 110 nM. BRD4 Inhibitor-18 has a hydrophobic acetylcyclopentanyl side chain. BRD4 Inhibitor-18 can significantly suppress the proliferation of MV-4-11 cells with high BRD4 level.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTYNB

Cat. No.: HY-124447

BTYNB is a potent and selective inhibitor of **IMP1** binding to c-Myc mRNA (**IC$_{50}$**=5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Myc inhibitor 4

Cat. No.: HY-139885

c-Myc inhibitor 4 is a potent, orally bioavailable **c-MYC-reducing** compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Myc inhibitor 5

Cat. No.: HY-145843

c-Myc inhibitor 5 (DA3) is a fluorescent, long chain-bridged bispurine that selectively targets the **c-MYC G-quadruplex** (**K$_D$** of 16 μM). c-Myc inhibitor 5 shows inhibition on c-MYC expression rather than other G4-driven oncogenes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMLD010509

(SDS-1-021)

Cat. No.: HY-119271

CMLD010509 (SDS-1-021) is a highly specific inhibitor of the **oncogenic translation program** supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EN4

Cat. No.: HY-134761

EN4 is a covalent ligand that targets cysteine 171 (C171) of **MYC**. EN4 is selective for **c-MYC** over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.



Purity: 96.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

hnRNPK-IN-1

Cat. No.: HY-135691

hnRNPK-IN-1 is a **heterogeneous nuclear ribonucleoprotein K (hnRNPK)** binding ligand with K_d values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter.



Purity: 97.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IRES-C11

Cat. No.: HY-124811

IRES-C11 is a spectfic **c-MYC internal ribosome entry site (IRES)** translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IZCZ-3

Cat. No.: HY-111411

IZCZ-3 is a potent **c-MYC transcription** inhibitor with antitumor activity.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

KJ Pyr 9

Cat. No.: HY-19735

KJ Pyr 9 is an inhibitor of **MYC** with a K_d of 6.5 nM in in vitro assay.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KSI-3716

Cat. No.: HY-12703

KSI-3716 is a potent **c-Myc** inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lusianthridin

Cat. No.: HY-121418

Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ML327

Cat. No.: HY-103038

ML327 is a blocker of **MYC** which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MYC-IN-2

Cat. No.: HY-141666

MYC-IN-2 is a **MYC protein-protein** inhibitor. MYC-IN-2 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

MYCi361

(NUCC-0196361)

Cat. No.: HY-129600

MYCi361 (NUCC-0196361) is a **MYC** inhibitor with the K_d of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MYCMI-6

(NSC354961)

Cat. No.: HY-124675

MYCMI-6 (NSC354961) is a potent and selective endogenous **MYC:MAX** protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a K_d of 1.6μM.



Purity: 95.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Mycro 3

Cat. No.: HY-100669

Mycro 3 is a potent and selective inhibitor of **Myc-associated factor X (MAX) dimerization**. Mycro 3 also inhibit DNA binding of c-Myc. Mycro 3 could be used for the research of pancreatic cancer.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NY2267

Cat. No.: HY-134975

NY2267 is a disruptor of **Myc-Max interaction**, with an IC_{50} of 36.5 μM. NY2267 inhibits Myc- and Jun-induced transcriptional activation.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

sAJM589

Cat. No.: HY-122683

sAJM589 is a **Myc** inhibitor which potently disrupts the Myc-Max heterodimer with an IC_{50} of 1.8 μM.



Purity: 99.65%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg

Stauprimide

Cat. No.: HY-N6747

Stauprimide is a staurosporine analog that promotes embryonic stem cell (ESC) differentiation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

VPC-70619

Cat. No.: HY-144878

VPC-70619 is a potent, orally active **N-Myc** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg